Table 1. Markers of talazoparib (PARP inhibitor) response in PDX models of SCLC.
Markers of Talazoparib Response in vivo (PDX) | |||
---|---|---|---|
Marker | P-value | Fold Change | |
Sensitivity | SLFN11 (protein) | 0.013 | 5.10 |
SLFN11 (mRNA) | 0.031 | 38.82 | |
E-cadherin (protein) | 0.158 | 2.24 | |
CDH1 (mRNA) | 0.137 | 7.11 | |
Resistance | EMT score | 0.05 | −2.24(mean difference) |
ATM (protein) | 0.009 | −2.32 | |
ATM (mRNA) | 0.004 | −2.12 | |
CHK1 (protein) | 0.017 | −1.48 | |
CHEK1 (mRNA) | 0.003 | −1.86 | |
IGF-1R (protein) | 0.044 | −1.73 | |
IRS1 (protein) | 0.025 | −1.39 | |
Not Associated | Myriad HRD | 0.748 | 1.081 |
FMI Non-germline mutations | 0.083 | −1.514 | |
FMI All mutations | 0.156 | −1.347 | |
PAR (ELISA) | 0.124 | 1.67 | |
PARP1 (protein) | 0.614 | −1.06 |